KDR and renal cell carcinoma: It is a receptor tyrosine kinase inhibitor that inhibits angiogenesis and RCC progression mainly by inhibiting the activities of platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) and receptor tyrosine kinase [9].